Melbourne, Australia; 22 December 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it has received the anticipated $3.5M of R&D tax incentive refund related to FY16 expenditures.

The R&D tax refund relates to eligible R&D expenditure across Starpharma’s portfolio of VivaGel^®, DEP^® drug delivery and agrochemical programs.

Commenting on the refund, Starpharma CEO Dr Jackie Fairley said:

“The R&D tax incentive is an important program for the biotech sector and provides a significant incentive for Starpharma to conduct R&D in Australia, and advance a diversified portfolio across the development product lifecycle. It fosters the ability for great Australian ideas to progress through early to late stage R&D to become commercialised, innovative products.

“The R&D incentive has helped facilitate valuable product opportunities including our: multiproduct DEP^® license with AstraZeneca and deals with other world-leading pharmaceutical companies; internal DEP^® programs; the series of VivaGel^® sexual health products; as well as agrochemical programs.”

Download ASX Announcement: Starpharma receives $3.5M R&D tax incentive refund (pdf file, 94kb)